Download
injecting and bbvs ndtms and prevalence data n.
Skip this Video
Loading SlideShow in 5 Seconds..
Injecting and BBVs – NDTMS and prevalence data PowerPoint Presentation
Download Presentation
Injecting and BBVs – NDTMS and prevalence data

Injecting and BBVs – NDTMS and prevalence data

98 Vues Download Presentation
Télécharger la présentation

Injecting and BBVs – NDTMS and prevalence data

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Injecting and BBVs – NDTMS and prevalence data • Current prevalence data for injecting among opiate/crack users (2010/11) shows continuation of a steady decline in the number of injectors Injecting and BBVs – NDTMS and prevalence data

  2. Injecting and BBVs – NDTMS and prevalence data • This is reflected in a decrease in the number and proportion of current injectors entering treatment – in 2011/12 this was 18% (~12,000) Injecting and BBVs – NDTMS and prevalence data

  3. Injecting and BBVs – NDTMS and prevalence data • NDTMS does not contain data on whether an individual has hepatitis B or hepatitis C, but rather whether they have been offered and received the appropriate vaccination or testing • Performance of providers against these indicators is monitored through routine reporting (e.g. DOMES) • Also submit data for use in regular Health Protection projects (Hep C estimates; Hepatitis C in the UK Report) Injecting and BBVs – NDTMS and prevalence data

  4. Injecting and BBVs – NDTMS and prevalence data • Uptake and receipt of hepatitis B vaccinations has declined slightly over the last three years Injecting and BBVs – NDTMS and prevalence data

  5. Injecting and BBVs – NDTMS and prevalence data • Rates of acceptance and receipt of hepatitis C tests among those with an injecting history have continued to increase over the last three years, although has levelled off in the past year Injecting and BBVs – NDTMS and prevalence data